Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Sulconazole induces PANoptosis to increase radiosensitivity of esophageal cancer by triggering oxidative stress and inhibiting glycolysis

ABSTRACT: Esophageal cancer is the seventh most common cancer in the world. Although traditional treatment methods such as radiotherapy and chemotherapy have good effects, their side effects and drug resistance are still obvious. The repositioning of drug function provides new ideas for the research and development of anticancer drugs. We previously identified a Food and Drug Administration (FDA) approved drugsulconazole can effectively inhibit the growth of esophageal cancer cells, but its molecular mechanism is not clear. Here, our study demonstrated that sulconazole had a broad spectrum of anticancer effects. It can not only inhibit the proliferation, but also inhibit the migration of esophageal cancer cells. Both transcriptomic sequencing and proteomic sequencing showed that sulconazole could promote various programmed cell death and inhibited glycolysis and its related signal pathways. Experimentally, wefound that sulconazole induced apoptosis, pyroptosis and ferroptosis. Mechanistically, sulconazole triggered mitochondrial oxidative stress, inhibited glycolysis and activating BCL2/Bax/Caspase3 axis. Finally, we discovered that low-dose sulconazole canincrease radiosensitivity of esophageal cancer cells. Taken together, these new findings provided strong laboratory evidence for the clinical application of sulconazole in esophageal cancer.

ORGANISM(S): Homo Sapiens

SUBMITTER: Liyan Xu

PROVIDER: PXD038874 | iProX | Sat Dec 17 00:00:00 GMT 2022

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Combinatorial targeting of glycolysis and oxidative phosphorylation suppresses tumor growth and metastases.

Project description:The Warburg effect, consisting of increased glucose uptake and glycolysis, provides metabolic energy as well as cellular building blocks for tumor growth. Inhibition of the Warburg effect with 2-deoxyglucose (2DG) has been explored in clinical trials with limited efficacy. Blockage of glycolysis can induce autopahgy resulting in alternative energy generation through oxidative phosphorylation providing a potential bypass of the effects of inhibition of glycolysis. Here in we demonstrate that activation of AMPK, as a consequence of energetic stress, induces mitochondrial energy production potentially bypassing the effects of glycolysis inhibition. We thus combined blockage of glycolysis by 2DG with inhibition of the electron transfer complex I (ETC1) in the mitochondria with the clinically applicable antidiabetic drug metformin. The combination resulted in activation of AMPK and autopahgy that however rendered eventual depletion of ATP and cell death. Furthermore, combined inhibition of glycolysis and mitochondrial respiration inhibited tumor growth and markedly decreased metastatic capacity in vivo. In order to understand the mechanism of these metabolic inhibitors, we performed whole genome transcriptional analysis. Human SK-4 esophageal cancer cell lines were treated with 5 different treatment groups [2 deoxy glucose (4mM), Metformin (5mM), AICAR (2mM), 2 deoxy glucose (4mM) plus Metformin (5mM) and 2 deoxy glucose (4mM) plus AICAR (2mM)] with non treated control groups for 12 hrs. Each groups was quadruplicated. Microarray experiments and data analysis were done at Dept. of Systems Biology, MDACC (Houston, USA)

2012-12-31 | E-GEOD-16816 | biostudies-arrayexpress

Agrimoniin synergistically works with erlotinib to inhibit the proliferation of pancreatic cancer by remodeling the tumor microenvironment and suppressing lactic acid expression

Project description:Erlotinib, as an EGFR small molecule inhibitor for pancreatic cancer, its efficacy as monotherapy is limited. Combination of erlotinib and gemcitabine has shown improvement in multiple survival indicators. However, drug resistance remains a challenge. Agrimoniin, the main active ingredient in Agrimonia pilosa, has anticancer potential. Whether it can serve as a synergistic or resistance-reversing drug for erlotinib require further research. In this study, we performed subcutaneous xenograft tumor experiments, CCK8, EdU assays, flow cytometry, HE staining, immunohistochemical and western blot to explore the synergistic effects of agrimoniin and erlotinib in inhibiting pancreatic cancer. Single-cell RNA sequencing was used to explore the relationship between their synergistic effects and tumor microenvironment. Through western blot and colorimetric assays for lactic acid, we studied the connection between their synergistic effects and aerobic glycolysis as well as lactic acid expression. By employing signal pathway inhibitors and agonists, we studied the positive feedback regulatory mechanism between relevant signal pathways and lactic acid expression. We found that agrimoniin and erlotinib synergistically inhibits the proliferation and promotes the apoptosis of pancreatic cancer cells. Together, they effectively suppress signal interaction among tumor cells, stromal cells and macrophages within subcutaneous tumors. They synergistically inhibit aerobic glycolysis and lactic acid expression in pancreatic cancer. Notably, we uncover the vicious cycle between the PI3K/AKT//HIF-1α/HK2, MEK/ERK/HIF-1α/HK2 signaling pathways and lactic acid expression. Combination of agrimoniin and erlotinib remodels tumor microenvironment, reprograms aerobic glycolysis, disrupts the positive feedback loop between lactic acid and two signaling pathways, thus synergistically inhibits the proliferation of pancreatic cancer cells.

2025-03-01 | GSE278383 | GEO

Next Generation Sequencing Facilitates Analysis of Penfluridol Treatment and Control SamplesTranscriptomes

Project description:Endometrial cancer (EC) is the most common cancer of the female reproductive tract and one of the few cancers for which survival has not substantially improved since the mid-1970s, reflecting few advances in treatment. The main therapeutic method of EC is surgical therapy assisted with radiotherapy and chemotherapy at present. Progesterone is the first-line drug for conservative treatment, but it faces the challenge of drug resistance and is ineffective for type II EC. There is an urgent clinical need to find new therapeutic targets and candidate drugs. Repurposing of existing drugs is a good strategy to discover new candidate drugs. Herein, 33 antipsychotics in our drug library were screened and penfluridol (PFD) was found to exhibit excelent anti-EC activity. Then the molecular target of PFD was revealed as the GTP-binding protein Septin7 using activity-based protein profiling (ABPP) techniques. Septin7 functioned as a tumor suppressor in EC and PFD exhibited weaker anticancer properties in Septin7 knockdown EC cells, indicating that Septin7 is essential for PFD biological activity. Notably, our investigations of PFD mechanism suggested that PFD binding with Septin7 inhibited the interaction of Septin7 with microtubules, thereby inhibiting microtubule polymerization and arresting the cell cycle in G1 phase. In addition, RNA-seq analysis and western blot showed that PFD could induce cell apoptosis by regulating Septin7-PIK3CA-AKT-Caspase3 pathway. Finally, PFD displayed significant in vivo antitumor efficacy in KLE endometrial cancer xenograft models without causing obvious side effects. Taken together, our findings revealed new target and mechanistic insights in EC therapeutic strategy and offer a potential candidate for the treatment of EC, especially progesterone resistance EC.

2023-12-25 | GSE236228 | GEO

ZNF750 is a lineage-specific tumor suppressor in squamous cell carcinoma [UMSCC1]

Project description:ZNF750 controls epithelial homeostasis by regulating epidermal-differentiation genes, a role underscored by its pathogenic mutations in esophageal squamous cell cancers (SCCs). However, the precise role of ZNF750 in SCC cell biology remains unclear. In this study, we report that ZNF750 is exclusively deleted, mutated and underexpressed in human SCCs, and low ZNF750 expression is associated with poor survival. Restoration of wildtype, but not mutant ZNF750 protein uniquely inhibited the malignant phenotype of SCC cells both in vitro and in vivo. Notably, ZNF750 promoted the expression of a LncRNA (TINCR) which mediated both cancer-inhibition and differentiation-induction effects of ZNF750. In addition, ZNF750 potently suppressed cell migration by directly inhibiting the transactivation of LAMC2. Together, our findings characterize ZNF750 as a crucial SCC-specific suppressor and uncover its novel anticancer-associated functions. RNA expression profile in UMSCC1 following ZNF750 wildtype overexpressing was analyzed by RNA-Seq.

2016-08-25 | E-GEOD-86014 | biostudies-arrayexpress

Antipsychotic Drug Trifluoperazine as a Potential Therapeutic Agent against Nasopharyngeal Carcinoma

Project description:Trifluoperazine (TFP), a typical antipsychotic primarily used for treating schizophrenia, exhibits anticancer effect on several types of cancer in recent years. Nevertheless, the effect of TFP on na-sopharyngeal carcinoma (NPC) is still unknown. In this study, we aimed to evaluate if TFP can be the potential therapeutic agent against NPC and to identify its underlying molecular mechanisms. We used four NPC cell lines, namely TW01, TW03, TW04, and BM, to assess the anticancer effects of TFP using cytotoxicity, wound healing, colony formation, and cell invasion assays. RNA se-quencing combined with Ingenuity Pathways Analysis was performed to identify the mechanism by which TFP influences NPC cells. Our data revealed that TFP decreased NPC cell viability in a dose-dependent manner. The invasion and migration of NPC cells were inhibited by TFP. RNA sequencing showed several anticancer molecular mechanisms after TFP administration. It is promising that the antipsychotic drug TFP can be used as a potential therapeutic regimen in NPC treatment in the future.

2023-12-21 | GSE192860 | GEO

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-FU-Mediated Cytotoxicity in Multiple Human Cancer Types

Project description:Toca 511 is a modified Retroviral Replicating Vector based on Moloney gâretrovirus with an amphotropic envelope. As an investigational cancer treatment, Toca 511 preferentially infects cancer cells without direct cell lysis and encodes an enhanced yeast cytosine deaminase that converts the antifungal drug 5âfluorocytosine to the anticancer drug, 5-fluorouracil. A panel of established human cancers cell lines, derived from glioblastoma, colon, and breast cancer tissue was used to evaluate parameters critical for effective anticancer activity. As part of these analyses, we profiled relative mRNA levels across these cell lines via RNA sequencing. mRNA expression profiles across nine human cancer cell lines.

2015-11-01 | E-GEOD-72955 | biostudies-arrayexpress

The study of the effects of dauricine(dau) on human pancreatic carcinoma cells [miRNA]

Project description:Pancreatic cancer is one of the most malignant digestive tract tumors with the worst prognosis. Few treatments are available; thus, the discovery of potential new anti-cancer agents has always been a hot issue. Dauricine (Dau) can inhibit the proliferation of the pancreatic cancer cell line BxPC3, and has the potential to be used as an adjuvant drug against pancreatic cancer; however, how Dau inhibits tumor cell proliferation has not been elucidated. To unravel the effects of Dau on proteins and metabolic pathways of pancreatic cancer cells, and to elucidate its anticancer mechanisms, we evaluated mRNA and microRNA expression in BxPC3 cells treated with Dau.

2021-06-05 | GSE176163 | GEO

The study of the effects of dauricine(dau) on human pancreatic carcinoma cells [mRNA array]

2021-06-05 | GSE176162 | GEO

Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergizes the anticancer effects of sorafenib in hepatocellular carcinoma

Project description:Sorafenib, a multiple-kinase inhibitor, has been widely used as a first-line anticancer drug for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance to sorafenib is frequently observed in clinical applications. Potential non-kinase targets of sorafenib have not been well documented and may provide insights into reversing drug resistance. Herein, we report that sorafenib exerted its anticancer effects by activating metallothionein 1G (MT1G) expression. MT1G served as a novel marker in HCC and correlated well with patient survival. MT1G overexpression suppressed the cellular proliferation, migration, invasion, and tumor formation of HCC, and sensitized cells to sorafenib treatment. However, the disruption of MT1G attenuated sorafenib’s anticancer effects. Mechanistically, sorafenib upregulated MT1G expression via hypomethylation of its promoter region by binding and inhibiting DNA methyltransferase 1 (DNMT1) and increasing its promoter accessibility in HCC cells. The activation of MT1G also inhibited CA9 transcription through the degradation of HIF1a as mediated by KLF4. Our collective data revealed that sorafenib exerted its anticancer effects through epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis in HCC, and that the activation of MT1G might constitute a strategy for reversing sorafenib resistance.

2022-04-30 | GSE192771 | GEO

Esculetin inhibits cancer cell glycolysis by binding tumor PGK2, GPD2, and GPI

Project description:Glycolysis can improve the tolerance of tissue cells to hypoxia, and its intermediates provide raw materials for the synthesis and metabolism of the tumor cells. If it can inhibit the activity of glycolysis-related enzymes and control the energy metabolism of tumor, it can be targeted for the treatment of malignant tumor. The target proteins phosphoglycerate kinase 2 (PGK2), glycerol-3-phosphate dehydrogenase (GPD2) and glucose-6-phosphate isomerase (GPI) were screened by combining transcriptome, proteomics and reverse docking. We detected the binding constant of the active compound using microscale thermophoresis (MST). It was found that esculetin bound well with three potential target proteins. Esculetin significantly inhibited the rate of glycolysis, manifested by differences of cellular lactate production and glucose consumption in HepG2 cells with or without esculetin. It was found that GPD2 bound strongly to GPI, revealing the direct interaction between the two glycolysis-related proteins. Animal tests have further demonstrated that esculetin may have anticancer effects by affecting the activity of PGK2, GPD2 and GPI. The results of this study demonstrated that esculetin can affect the glucose metabolism by binding to glycolytic proteins, thus playing an anti-tumor role, and these proteins which have direct interactions are potential novel targets for tumor treatment by esculetin.

2020-03-03 | PXD017819 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data